Clinical applications of PD-L1 bioassays for cancer immunotherapy

Journal of Hematology & Oncology
Delong LiuWendy Bindeman

Abstract

Programmed death ligand 1 (PD-L1) has emerged as a biomarker that can help to predict responses to immunotherapies targeted against PD-L1 and its receptor (PD-1). Companion tests for evaluating PD-L1 expression as a biomarker of response have been developed for many cancer immunotherapy agents. These assays use a variety of detection platforms at different levels (protein, mRNA), employ diverse biopsy and surgical samples, and have disparate positivity cutoff points and scoring systems, all of which complicate the standardization of clinical decision-making. This review summarizes the current understanding and ongoing investigations regarding PD-L1 expression as a potential biomarker for clinical outcomes of anti-PD-1/PD-L1 immunotherapy.

References

May 9, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·M K Oaks, K M Hallett
Jun 1, 2000·Cellular Immunology·M K OaksA J Tector
Aug 7, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jun KonishiMasaharu Nishimura
Mar 1, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xavier FrigolaEugene D Kwon
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Nov 22, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Evan J LipsonSuzanne L Topalian
Jan 15, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Anne M SchultheisReinhard Buettner
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Jun 26, 2015·Journal of Hematology & Oncology·Sai Mun LeongEvelyn S C Koay
Jul 3, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Keith M KerrUNKNOWN IASLC Pathology Committee
Aug 1, 2015·Journal of Hematology & Oncology·Wei SunKongming Wu
Sep 1, 2015·Applied Immunohistochemistry & Molecular Morphology : AIMM·Therese PhillipsXiaoling Zhang
Dec 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Aaron S MansfieldMarie Christine Aubry
Jan 13, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David F McDermottThomas Powles
Feb 24, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ching-Yao YangPan-Chyr Yang
Feb 27, 2016·Oncotarget·Francesco PassigliaAntonio Russo
May 18, 2016·Diagnostic Pathology·Jacquelyn SmithH James Hnatyszyn
Jun 9, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe MassardNeil H Segal
Jan 1, 2015·Experimental Hematology & Oncology·Eddy C Hsueh, Kalyan C Gorantla
Aug 20, 2016·JAMA Oncology·Patricia GauleDavid L Rimm
Aug 24, 2016·Archives of Pathology & Laboratory Medicine·Marisa Dolled-FilhartKenneth Emancipator
Oct 22, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Chee Khoon LeeJames Chih-Hsin Yang
Nov 1, 2016·Nature Communications·Ju Yeon LeeYong-Seok Heo
Nov 20, 2016·Journal of Hematology & Oncology·Xia FangJunke Zheng
Dec 4, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Fred R HirschKeith M Kerr
Dec 8, 2016·International Journal of Cancer. Journal International Du Cancer·Sheng ChenZhi-Ming Shao
Dec 13, 2016·Journal of Hematology & Oncology·Bhagirathbhai DholariaYanyan Lou

❮ Previous
Next ❯

Citations

Mar 28, 2018·Journal of Hematology & Oncology·Ming YiKongming Wu
Dec 9, 2017·Future Oncology·Kevin T LundgrenJoaquim Bellmunt
Jan 30, 2018·Journal of Immunology Research·Fu-Shun HsuKou-How Huang
Feb 2, 2018·Journal of Hematology & Oncology·Xin LiKen H Young
Oct 22, 2018·Pigment Cell & Melanoma Research·Goran MicevicMarcus W Bosenberg
May 3, 2019·Journal of Hematology & Oncology·Sen YangQiming Wang
Sep 16, 2019·Journal of Hematology & Oncology·Anping LiKongming Wu
Sep 7, 2019·Journal of Hematology & Oncology·Akintunde Akinleye, Zoaib Rasool
Apr 12, 2019·International Journal of Molecular Sciences·Valentina ZuccaroRaffaele Bruno
Nov 15, 2019·Scientific Reports·Sasagu KurozumiKen Shirabe
Apr 24, 2020·Frontiers in Immunology·Yanyan TangQianjin Liao
Aug 25, 2018·Molecular Cancer·Ming YiKongming Wu
Jun 17, 2020·The Journal of Clinical Investigation·Rachael L TerryPaul J Neeson
Aug 9, 2018·Experimental Hematology & Oncology·Sowmini Medavaram, Yue Zhang
Nov 27, 2018·Experimental Hematology & Oncology·Ming YiKongming Wu
Oct 24, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jianming XuQuanren Wang
Feb 16, 2021·Chemical Communications : Chem Comm·Parisa MoazzamJ Justin Gooding
Sep 18, 2017·Seminars in Cancer Biology·Margaret L AxelrodJustin M Balko
May 29, 2021·Cancer Management and Research·Yaqi Jia, Tao Huang
Sep 16, 2020·Seminars in Cancer Biology·Olivia Le SauxS Intidhar Labidi-Galy

❮ Previous
Next ❯

Methods Mentioned

BETA
RNA-seq
biopsy
biopsies

Clinical Trials Mentioned

NCT01693562

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Raoul A DroeserLuigi Tornillo
Expert Review of Anticancer Therapy
Gautam Kishore ValechaJean Paul Atallah
Clinical Advances in Hematology & Oncology : H&O
Stephen J BagleyCorey J Langer
© 2022 Meta ULC. All rights reserved